Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

@article{Maude2018TisagenlecleucelIC,
  title={Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.},
  author={Shannon L Maude and Theodore W. Laetsch and Jochen Buechner and Susana Rives and Michael W. Boyer and Henrique von Hertwig Bittencourt and Peter Bader and Michael R Verneris and Heather E Stefanski and Gary Douglas Myers and Muna Qayed and Barbara De Moerloose and Hidefumi Hiramatsu and Krysta D Schlis and Kara L. Davis and Paul Langlie Martin and Eneida R Nemecek and Gregory Anthony Yanik and Christina Peters and Andr{\'e} Baruchel and Nicolas Boissel and Françoise M{\'e}chinaud and Adriana Balduzzi and Joerg Krueger and Carl H June and Bruce L Levine and Patricia A. Wood and Tetiana Taran and Mimi Leung and Karen Thudium Mueller and Yiyun Zhang and Kapildeb Sen and David Edward Lebwohl and Michael A Pulsipher and Stephan A. Grupp},
  journal={The New England journal of medicine},
  year={2018},
  volume={378 5},
  pages={
          439-448
        }
}
BACKGROUND In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 157 CITATIONS, ESTIMATED 63% COVERAGE

Active Immunotherapy in cancer – Current Status

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia

  • Journal of the advanced practitioner in oncology
  • 2018
VIEW 7 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Associated Toxicities: Assessment and Management Related to CAR T-Cell Therapy.

  • Clinical journal of oncology nursing
  • 2019
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2018
2019

CITATION STATISTICS

  • 21 Highly Influenced Citations

  • Averaged 78 Citations per year from 2018 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…